Nautical mile

Students' Lemonade Stand Fundraiser Sets Ambitious Goal of Raising $14,500 for Children's Hospital

Retrieved on: 
Wednesday, January 17, 2024
Student, Hope, Learning, National School Choice Week, Multimedia, Partnership, School, Discovery, Cancer, Entrepreneurship, Nautical mile, Technology museum, Hospital, Creativity, Organization, Parent, Opportunity, Education, National school, Week, Soft drink

MILWAUKEE, Jan. 17, 2024 /PRNewswire/ -- Students at seven schools are joining forces next week for a lemonade stand fundraiser with a big goal: collectively raising $14,500 for children with cancer. The annual student-led campaign, which is planned to coincide with National School Choice Week, is an impressive celebration of unity, entrepreneurship, and philanthropy in the community.

Key Points: 
  • LUMIN Opportunity Day to celebrate entrepreneurship, philanthropy, and school choice
    MILWAUKEE, Jan. 17, 2024 /PRNewswire/ -- Students at seven schools are joining forces next week for a lemonade stand fundraiser with a big goal: collectively raising $14,500 for children with cancer.
  • These stands represent months of hard work and student partnership with local artisans and businesses, who assist students in preparing their lemonade stands.
  • The grand tally will be revealed at the follow-up LUMIN Opportunity Day on Thursday, Jan. 25 at Discovery World Science and Technology Museum.
  • While lemonade may seem like a cool refreshment for chilly January, event planners say students spread warmth and hope with every cup sold.

Silent Arrow® Awarded AFWERX Contract to Develop a Long-Range Powered Cargo Drone

Retrieved on: 
Monday, December 18, 2023
Air force, Organization, AFWERX, Airbus, Nautical mile, Lockheed Martin, DAF, Arrow, SBIR, A400M, Boeing, AFRL, C-17, Lockheed, Travel, Airline

LOS ANGELES, Dec. 18, 2023 /PRNewswire/ -- Silent Arrow today announced it has been selected by AFWERX for a SBIR contract focused on the Silent Arrow CLS-300 ("Contested Logistics System, 300 Nautical Miles") to address one of the most pressing challenges in the Department of the Air Force (DAF).

Key Points: 
  • LOS ANGELES, Dec. 18, 2023 /PRNewswire/ -- Silent Arrow today announced it has been selected by AFWERX for a SBIR contract focused on the Silent Arrow CLS-300 ("Contested Logistics System, 300 Nautical Miles") to address one of the most pressing challenges in the Department of the Air Force (DAF).
  • The CLS-300 is based on the commercially successful Silent Arrow GD-2000, the world's first heavy payload, autonomous and attritable cargo delivery aircraft designed to carry 1,500 lbs.
  • of cargo over 35 nautical miles when deployed from cargo aircraft such as the Lockheed Martin C-130, Boeing C-17 and Airbus A400M.
  • "We'd like to thank the U.S. Air Force, AFWERX, AFRL and our Air Force Customer and End-User organizations for their confidence in awarding this disruptive program," said Chip Yates, Silent Arrow's Founder and CEO.

Iridium Proposes a New Model for Monitored BVLOS UAS Integration in the National Airspace System

Retrieved on: 
Tuesday, June 20, 2023
Aircraft, Federal Aviation Administration, Communication, Partnership, Iridium Communications, UAS, NAS, Remote, National Airspace System, IRDM, FAA, VFR, Risk, Nautical mile, Medium-altitude long-endurance unmanned aerial vehicle, MEL, Radio, Commercial, LOS, Visual flight rules, COTS, LTE, Instrument flight rules, Maxima and minima, Airline, Platinum, Iridium, Aviation

MCLEAN, Va., June 20, 2023 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ: IRDM) has announced the results of an Uncrewed Aircraft System (UAS) flight trial highlighting Beyond Visual Line of Sight (BVLOS) capabilities in the National Airspace System (NAS), with a published a whitepaper titled "Monitored BVLOS: A New Model for UAS Integration in the National Airspace System." The whitepaper highlights and solves for challenges faced in enabling a safe, scalable, and efficient adoption of UAS in the NAS, including how to maintain safe separation of aircraft and what supportive Commercial Off-the-Shelf (COTS) avionics are readily available.

Key Points: 
  • MCLEAN, Va., June 20, 2023 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ: IRDM) has announced the results of an Uncrewed Aircraft System (UAS) flight trial highlighting Beyond Visual Line of Sight (BVLOS) capabilities in the National Airspace System (NAS), with a published a whitepaper titled " Monitored BVLOS: A New Model for UAS Integration in the National Airspace System ."
  • The RPIC successfully performed a BVLOS evasive maneuver in less than 18 seconds from detection to completion, maintaining two NM of separation with nonidealized operations.
  • The results also showed that BVLOS operations are ideal for Class E airspace, as it presents a greatly reduced risk of encountering other crewed Visual Flight Rules (VFR) aircraft.
  • For a copy of Iridium's BVLOS whitepaper, visit: www.iridium.com/monitored-bvlos-safe-separation-whitepaper/
    For more information about Iridium, visit: www.iridium.com

Iridium Proposes a New Model for Monitored BVLOS UAS Integration in the National Airspace System

Retrieved on: 
Tuesday, June 20, 2023
Aircraft, Federal Aviation Administration, Communication, Partnership, Iridium Communications, UAS, NAS, Remote, National Airspace System, IRDM, FAA, VFR, Risk, Nautical mile, Medium-altitude long-endurance unmanned aerial vehicle, MEL, Radio, Commercial, LOS, Visual flight rules, COTS, LTE, Instrument flight rules, Maxima and minima, Airline, Platinum, Iridium, Aviation

MCLEAN, Va., June 20, 2023 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ: IRDM) has announced the results of an Uncrewed Aircraft System (UAS) flight trial highlighting Beyond Visual Line of Sight (BVLOS) capabilities in the National Airspace System (NAS), with a published a whitepaper titled "Monitored BVLOS: A New Model for UAS Integration in the National Airspace System." The whitepaper highlights and solves for challenges faced in enabling a safe, scalable, and efficient adoption of UAS in the NAS, including how to maintain safe separation of aircraft and what supportive Commercial Off-the-Shelf (COTS) avionics are readily available.

Key Points: 
  • MCLEAN, Va., June 20, 2023 /PRNewswire/ -- Iridium Communications Inc. (NASDAQ: IRDM) has announced the results of an Uncrewed Aircraft System (UAS) flight trial highlighting Beyond Visual Line of Sight (BVLOS) capabilities in the National Airspace System (NAS), with a published a whitepaper titled " Monitored BVLOS: A New Model for UAS Integration in the National Airspace System ."
  • The RPIC successfully performed a BVLOS evasive maneuver in less than 18 seconds from detection to completion, maintaining two NM of separation with nonidealized operations.
  • The results also showed that BVLOS operations are ideal for Class E airspace, as it presents a greatly reduced risk of encountering other crewed Visual Flight Rules (VFR) aircraft.
  • For a copy of Iridium's BVLOS whitepaper, visit: www.iridium.com/monitored-bvlos-safe-separation-whitepaper/
    For more information about Iridium, visit: www.iridium.com

Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease at the WORLDSymposium 2023

Retrieved on: 
Thursday, February 16, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Patient, Research, Therapy, Standard of care, Nautical mile, Glycogen storage disease type II, HIV disease progression rates, Clinical trial, Pharmaceutical industry, Maze

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present data from its first-in-human clinical trial of MZE001 in healthy volunteers at the WORLDSymposium 2023.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present data from its first-in-human clinical trial of MZE001 in healthy volunteers at the WORLDSymposium 2023.
  • In addition, the company will present a novel non-invasive biomarker for therapeutic intervention in Pompe disease and further preclinical work supporting the program’s advancement.
  • MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen accumulation, is being evaluated for the potential treatment of patients with Pompe disease.
  • The WORLDSymposium is being held February 22-26, 2023, in Orlando.